S304: SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, PROVIDES SUSTAINED IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): 2 YEAR FOLLOW-UP FROM THE CARDINAL STUDY

• A. Röth,
• C. M. Broome,
• W. Barcellini,
• T. Henrik Anderson Tvedt,
• Y. Miyakawa,
• S. D’Sa,
• D. Cella,
• F. Joly,
• J. Wang,
• T. Sourdille,
• F. Shafer,
• M. Wardęcki,
• I. C. Weitz

Affiliations

A. Röth

1 Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

C. M. Broome

2 Division of Hematology, MedStar Georgetown University Hospital, Washington, DC, United States of America

W. Barcellini

3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

T. Henrik Anderson Tvedt

4 Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen, Norway

Y. Miyakawa

5 Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama, Japan

S. D’Sa

6 UCLH Centre for Waldenström’s Macroglobulinemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London, United Kingdom

D. Cella

7 Department of Medical Social Sciences, Center for Patient-Centered Outcomes, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States of America

F. Joly

8 Sanofi, Chilly-Mazarin, France

J. Wang

9 Sanofi, Cambridge, MA

T. Sourdille

9 Sanofi, Cambridge, MA

F. Shafer

10 Sanofi, Bridgewater, NJ, United States of America

M. Wardęcki

11 Sanofi, Warsaw, Poland

I. C. Weitz

12 Keck School of Medicine of USC, Los Angeles, CA, United States of America